Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Yadlapati, Sujani ^a   Efthimiou, Petros ^a,b  

^a NEW YORK METHODIST HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ARTHRITIS; AUTOIMMUNE ARTHRITIS; AUTOINFLAMMATORY DISEASE; CANCER RISK; CELIAC DISEASE; DERMATOMYOSITIS; DISEASE ASSOCIATION; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; NONHODGKIN LYMPHOMA; POLYMYOSITIS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; AUTOIMMUNE DISEASE; COMPLICATION; INCIDENCE; INFLAMMATION; RISK;

ARTHRITIS; AUTOIMMUNE DISEASES; HUMANS; INCIDENCE; INFLAMMATION; LYMPHOMA; RISK;

EID: 84982836500     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/8631061     Document Type: Review

References (108)

1. D. M. Parkin, "Global cancer statistics in the year 2000, " The Lancet Oncology, vol. 2, no. 9, pp. 533-543, 2001.
2. K. E. Smedby, E. Baecklund, and J. Askling, "Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics, " Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 11, pp. 2069-2077, 2006.
3. K. E. Smedby, J. Askling, X. Mariette, and E. Baecklund, "Autoimmune and inflammatory disorders and risk of malignant lymphomas-an update, " Journal of Internal Medicine, vol. 264, no. 6, pp. 514-527, 2008.
4. E. Baecklund, A. Iliadou, J. Asklinget al., "Associationof chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis, " Arthritis & Rheumatism, vol. 54, no. 3, pp. 692-701, 2006.
5. E. S. Jaffe, N. L. Harris, H. Stein, and J. W. Vardiman, Eds., Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues, IARC Press, Lyon, France, 2001.
6. E. Baecklund, C. Sundström, A. Ekbom et al., "Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma, " Arthritis and Rheumatism, vol. 48, no. 6, pp. 1543-1550, 2003.
7. K. E. Smedby, H. Hjalgrim, J. Askling et al., "Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype, " Journal of the National Cancer Institute, vol. 98, no. 1, pp. 51-60, 2006.
8. E. Baecklund, C. Backlin, A. Iliadou et al., "Characteristics of diffuse large B-cell lymphomas in rheumatoid arthritis, " Arthritis and Rheumatism, vol. 54, no. 12, pp. 3774-3781, 2006.
9. E. Baecklund, Y. Natkunam, C. Backlin et al., "Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis, " British Journal of Haematology, vol. 141, no. 1, pp. 69-72, 2008.
10. B. Löfström, C. Backlin, T. Pettersson, I. E. Lundberg, and E. Baecklund, "Expression of APRIL in diffuse large B cell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis, " Journal of Rheumatology, vol. 38, no. 9, pp. 1891-1897, 2011.
11. E. Thomas, D. H. Brewster, R. J. Black, and G. J. Macfarlane, "Risk of malignancy among patients with rheumatic conditions, " International Journal of Cancer, vol. 88, no. 3, pp. 497-502, 2000.
12. X. Mariette, M. Matucci-Cerinic, K. Pavelka et al., "Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis, " Annals of the Rheumatic Diseases, vol. 70, no. 11, pp. 1895-1904, 2011.
13. K. Ekström, H. Hjalgrim, L. Brandt et al., "Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives, " Arthritis&Rheumatism, vol. 48, no. 4, pp. 963-970, 2003.
14. L. Abásolo, E. Júdez, M. A. Descalzo, I. González-Alvaro, J. A. Jover, and L. Carmona, "Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population, " Seminars in Arthritis and Rheumatism, vol. 37, no. 6, pp. 388-397, 2008.
15. F. Wolfe and K. Michaud, "Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18, 572 patients, " Arthritis & Rheumatism, vol. 50, no. 6, pp. 1740-1751, 2004.
16. K. Hemminki, X. Li, K. Sundquist, and J. Sundquist, "Cancer risk in hospitalized rheumatoid arthritis patients, " Rheumatology, vol. 47, no. 5, pp. 698-701, 2008.
17. L. A. Anderson, S. Gadalla, L. M. Morton et al., "Populationbased study of autoimmune conditions and the risk of specific lymphoid malignancies, " International Journal of Cancer, vol. 125, no. 2, pp. 398-405, 2009.
18. J. Askling, E. Baecklund, F. Granath et al., "Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: Relative risks and time trends in the Swedish Biologics Register, " Annals of the Rheumatic Diseases, vol. 68, no. 5, pp. 648-653, 2009.
19. A. Parikh-Patel, R. H. White, M. Allen, and R. Cress, "Risk of cancer among rheumatoid arthritis patients in California, " Cancer Causes and Control, vol. 20, no. 6, pp. 1001-1010, 2009.
20. K. Hellgren, K. E. Smedby, N. Feltelius, E. Baecklund, and J. Askling, "Do rheumatoid arthritis and lymphoma share risk factors?: A comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis, " Arthritis & Rheumatism, vol. 62, no. 5, pp. 1252-1258, 2010.
21. Y.-J. Chen, Y.-T. Chang, C.-B. Wang, andC.-Y. Wu, "Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan, " American Journal of Medicine, vol. 123, no. 12, pp. 1150. e1-1150. e6, 2010.
22. L. K. Mercer, R. Davies, J. B. Galloway et al., "Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population, " Rheumatology, vol. 52, no. 1, pp. 91-98, 2013.
23. L. Dreyer, L. Mellemkjær, A. R. Andersen et al., "Incidences of overall and site specific cancers in TNF inhibitor treated patients with rheumatoid arthritis and other arthritides-a follow-up study from the DANBIO Registry, " Annals of the Rheumatic Diseases, vol. 72, no. 1, pp. 79-82, 2013.
24. W. Zhang, S. Feng, S. Yan et al., "Incidence ofmalignancy in primary Sjögren's syndrome in a Chinese cohort, " Rheumatology, vol. 49, no. 3, pp. 571-577, 2010.
25. R. Solans-Laqué, A. López-Hernandez, J. Angel Bosch-Gil, A. Palacios, M. Campillo, and M. Vilardell-Tarres, "Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome, " Seminars in Arthritis and Rheumatism, vol. 41, no. 3, pp. 415-423, 2011.
26. M.-Y. Weng, Y.-T. Huang, M.-F. Liu, and T.-H. Lu, "Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjögren's syndrome inTaiwan, " Annals of the Rheumatic Diseases, vol. 71, no. 4, pp. 524-527, 2012.
27. S. J. Johnsen, J. G. Brun, L. G. Gøransson et al., "Risk of non-Hodgkin's lymphoma in primary Sjogren's syndrome: a population-based study, " Arthritis Care & Research, vol. 65, no. 5, pp. 816-821, 2013.
28. Y. Liang, Z. Yang, B. Qin, and R. Zhong, "Primary Sjögren's syndrome and malignancy risk: a systematic review and metaanalysis, " Annals of the Rheumatic Diseases, vol. 73, no. 6, pp. 1151-1156, 2014.
29. N. Feltelius, A. Ekbom, and P. Blomqvist, "Cancer incidence among patients with ankylosing spondylitis in Sweden 1965-95: a population based cohort study, " Annals of the Rheumatic Diseases, vol. 62, no. 12, pp. 1185-1188, 2003.
30. A. Shibata, S. Zhao, R. Makuch, J. Wentworth, J. Veith, and W. Wallis, "Lymphoma risk in ankylosing spondylitis patients is greater than that observed in the general population, " Annals of the Rheumatic Diseases, vol. 63, supplement 1, p. 98, 2004.
31. N. Becker, E. Deeg, T. Rüdiger, and A. Nieters, "Medical history and risk for lymphoma: results of a population-based casecontrol study in Germany, " European Journal of Cancer, vol. 41, no. 1, pp. 133-142, 2005.
32. J. Askling, L. Klareskog, P. Blomqvist, M. Fored, and N. Feltelius, "Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study, " Annals of the Rheumatic Diseases, vol. 65, no. 9, pp. 1184-1187, 2006.
33. L. Mellemkjaer, R. M. Pfeiffer, E. A. Engels et al., "Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma, " Arthritis & Rheumatism, vol. 58, no. 3, pp. 657-666, 2008.
34. S. Rohekar, B. D. M. Tom, A. Hassa, C. T. Schentag, V. T. Farewell, and D. D. Gladman, "Prevalence of malignancy in psoriatic arthritis, " Arthritis & Rheumatism, vol. 58, no. 1, pp. 82-87, 2008.
35. R. L. Gross, J. S. Schwartzman-Morris, M. Krathen et al., "A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large us cohort, " Arthritis and Rheumatology, vol. 66, no. 6, pp. 1472-1481, 2014.
36. O. Nived, A. Bengtsson, A. Jönsen, G. Sturfelt, and H. Olsson, "Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden, " Lupus, vol. 10, no. 7, pp. 500-504, 2001.
37. J. Cibere, J. Sibley, andM. Haga, "Systemic lupus erythematosus and the risk of malignancy, " Lupus, vol. 10, no. 6, pp. 394-400, 2001.
38. L. Björn?adal, B. Löfström, L. Yin, I. E. Lundberg, andA. Ekbom, "Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus, " Scandinavian Journal of Rheumatology, vol. 31, no. 2, pp. 66-71, 2002.
39. T. Tarr, B. Gyorfy, é. Szekanecz et al., "Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: results from a single center, " Annals of the New York Academy of Sciences, vol. 1108, pp. 76-82, 2007.
40. A. Parikh-Patel, R. H. White, M. Allen, and R. Cress, "Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California, " Cancer Causes and Control, vol. 19, no. 8, pp. 887-894, 2008.
41. K. Y. Kang, H. O. Kim, H. S. Yoon et al., "Incidence of cancer among female patients with systemic lupus erythematosus in Korea, " Clinical Rheumatology, vol. 29, no. 4, pp. 381-388, 2010.
42. L. Dreyer, M. Faurschou, M. Mogensen, and S. Jacobsen, "High incidence of potentially virus-inducedmalignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort, " Arthritis and Rheumatism, vol. 63, no. 10, pp. 3032-3037, 2011.
43. S. Bernatsky, R. Ramsey-Goldman, J. Labrecque et al., "Cancer risk in systemic lupus: an updated international multi-centre cohort study, " Journal of Autoimmunity, vol. 42, pp. 130-135, 2013.
44. C. L. Hill, Y. Zhang, B. Sigurgeirsson et al., "Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study, " The Lancet, vol. 357, no. 9250, pp. 96-100, 2001.
45. D. Stockton, V. R. Doherty, and D. H. Brewster, "Risk of cancer in patients with dermatomyositis or polymyositis, and followup implications: a Scottish population-based cohort study, " British Journal of Cancer, vol. 85, no. 1, pp. 41-45, 2001.
46. G. Frentz and J. H. Olsen, "Malignant tumours and psoriasis: a follow-up study, " British Journal of Dermatology, vol. 140, no. 2, pp. 237-242, 1999.
47. P. Boffetta, G. Gridley, and B. Lindelöf, "Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden, " Journal of Investigative Dermatology, vol. 117, no. 6, pp. 1531-1537, 2001.
48. F. Wolfe and K. Michaud, "The effect of methotrexate and antitumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19, 562 patients during 89, 710 personyears of observation, " Arthritis and Rheumatism, vol. 56, no. 5, pp. 1433-1439, 2007.
49. P. Geborek, A. Bladström, C. Turesson et al., "Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas, " Annals of the RheumaticDiseases, vol. 64, no. 5, pp. 699-703, 2005.
50. J. Askling, C. M. Fored, E. Baecklund et al., "Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists, " Annals of the Rheumatic Diseases, vol. 64, no. 10, pp. 1414-1420, 2005.
51. S. Setoguchi, D. H. Solomon, M. E. Weinblatt et al., "Tumor necrosis factor antagonist use and cancer in patients with rheumatoid arthritis, " Arthritis and Rheumatism, vol. 54, no. 9, pp. 2757-2764, 2006.
52. F. Wolfe and K. Michaud, "Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18, 572 patients, " Arthritis and Rheumatism, vol. 50, no. 6, pp. 1740-1751, 2004.
53. R. Buchbinder, M. Barber, L. Heuzenroeder et al., "Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate, " Arthritis Care & Research, vol. 59, no. 6, pp. 794-799, 2008.
54. B. Royer, D. Cazals-Hatem, J. Sibilia et al., "Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses, " Blood, vol. 90, no. 2, pp. 766-775, 1997.
55. M. Voulgarelis, U. G. Dafni, D. A. Isenberg, and H. M. Moutsopoulos, "Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European concerted action on Sjogren's syndrome, " Arthritis & Rheumatism, vol. 42, no. 8, pp. 1765-1772, 1999.
56. A. Ambrosetti, R. Zanotti, C. Pattaro et al., "Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection, " British Journal of Haematology, vol. 126, no. 1, pp. 43-49, 2004.
57. S. M. Cohen, M. Petryk, M. Varma, P. S. Kozuch, E. D. Ames, and M. L. Grossbard, "Non-Hodgkin's lymphoma of mucosaassociated lymphoid tissue, " Oncologist, vol. 11, no. 10, pp. 1100-1117, 2006.
58. P. Youinou, V. Devauchelle-Pensec, and J.-O. Pers, "Significance of B cells and B cell clonality in Sjögren's syndrome, " Arthritis and Rheumatism, vol. 62, no. 9, pp. 2605-2610, 2010.
59. D. Cornec, V. Devauchelle-Pensec, G. J. Tobón, J.-O. Pers, S. Jousse-Joulin, and A. Saraux, "B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment, " Journal of Autoimmunity, vol. 39, no. 3, pp. 161-167, 2012.
60. C. Dias and D. A. Isenberg, "Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma, " Nature Reviews Rheumatology, vol. 7, no. 6, pp. 360-368, 2011.
61. S. Bernatsky, J. F. Boivin, L. Joseph et al., "An international cohort study of cancer in systemic lupus erythematosus, " Arthritis and Rheumatism, vol. 52, no. 5, pp. 1481-1490, 2005.
62. T. Okada, F. Takiura, K. Tokushige et al., "Major histocompatibility complex controls clonal proliferation of CD5+ B cells in H-2-congenic New Zealand mice: a model for B cell chronic lymphocytic leukemia and autoimmune disease, " European Journal of Immunology, vol. 21, no. 11, pp. 2743-2748, 1991.
63. A. Illes, L. Varoczy, G. Papp et al., "Aspects of B-cell non-Hodgkin's lymphoma development: a transition from immunereactivity to malignancy, " Scandinavian Journal of Immunology, vol. 69, no. 5, pp. 387-400, 2009.
64. R. W. Hoffman, "T cells in the pathogenesis of systemic lupus erythematosus, " Clinical Immunology, vol. 113, no. 1, pp. 4-13, 2004.
65. Y. Zhang, T. R. Holford, B. Leaderer et al., "Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in connecticut United States women, " Cancer Causes and Control, vol. 15, no. 4, pp. 419-428, 2004.
66. G. Gridley, J. H. Klippel, R. N. Hoover, and J. F. Fraumeni Jr., "Incidence of cancer among men with the Felty syndrome, " Annals of Internal Medicine, vol. 120, no. 1, pp. 35-39, 1994.
67. F. Wolfe, "Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkin's lymphoma in rheumatoid arthritis: a 25-year study of 1, 767 RA patients, " Arthritis & Rheumatology, vol. 41, no. 9, p. S188, 1998.
68. M. Kauppi, E. Pukkala, and H. Isomäki, "Elevated incidence of hematologic malignancies in patients with Sjogren's syndrome compared with patients with rheumatoid arthritis (Finland), " Cancer Causes and Control, vol. 8, no. 2, pp. 201-204, 1997.
69. E. Theander, G. Henriksson, O. Ljungberg, T. Mandl, R. Manthorpe, and L. T. H. Jacobsson, "Lymphoma and other malignancies in primary Sjögren's syndrome: A Cohort Study on Cancer Incidence and Lymphoma Predictors, " Annals of the Rheumatic Diseases, vol. 65, no. 6, pp. 796-803, 2006.
70. E. Baimpa, I. J. Dahabreh, M. Voulgarelis, and H. M. Moutsopoulos, "Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects, " Medicine, vol. 88, no. 5, pp. 284-293, 2009.
71. R. Solans-Laqué, A. López-Hernandez, J. A. Bosch-Gil, A. Palacios, M. Campillo, and M. Vilardell-Tarres, "Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome, " Seminars in Arthritis and Rheumatism, vol. 41, no. 3, pp. 415-423, 2011.
72. L. Quartuccio, M. Isola, C. Baldini et al., "Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study, " Journal of Autoimmunity, vol. 51, pp. 75-80, 2014.
73. M. Ramos-Casals, P. Brito-Zerón, M. Perez-De-Lis et al., "Clinical and prognostic significance of parotid scintigraphy in 405 patients with primary Sjögren's syndrome, " Journal of Rheumatology, vol. 37, no. 3, pp. 585-590, 2010.
74. E. Theander, L. Vasaitis, E. Baecklund et al., "Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome, " Annals of the Rheumatic Diseases, vol. 70, no. 8, pp. 1363-1368, 2011.
75. M. J. Leandro and D. A. Isenberg, "Rheumatic diseases and malignancy-is there an association?" Scandinavian Journal of Rheumatology, vol. 30, no. 4, pp. 185-188, 2001.
76. S. Bernatsky, R. Ramsey-Goldman, R. Rajan et al., "Non-Hodgkin's lymphoma in systemic lupus erythematosus, " Annals of the Rheumatic Diseases, vol. 64, no. 10, pp. 1507-1509, 2005.
77. S. Bernatsky, R. Ramsey-Goldman, L. Joseph et al., "Lymphoma risk in systemic lupus: effects of disease activity versus treatment, " Annals of the Rheumatic Diseases, vol. 73, no. 1, pp. 138-142, 2013.
78. J. K. King and K. H. Costenbader, "Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL), " Clinical Rheumatology, vol. 26, no. 9, pp. 1491-1494, 2007.
79. B. Löfström, C. Backlin, C. Sundström, A. Ekbom, and I. E. Lundberg, "Acloser look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study, " Annals of the Rheumatic Diseases, vol. 66, no. 12, pp. 1627-1632, 2007.
80. S. Bernatsky, L. Joseph, J.-F. Boivin et al., "The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study, " Annals of the Rheumatic Diseases, vol. 67, no. 1, pp. 74-79, 2008.
81. B. Sigurgeirsson, B. Lindelöf, O. Edhag, and E. Allander, "Risk of cancer in patientswith dermatomyositis or polymyositis, "The New England Journal of Medicine, vol. 326, no. 6, pp. 363-367, 1992.
82. J. M. Gelfand, D. B. Shin, A. L. Neimann, X. Wang, D. J. Margolis, and A. B. Troxel, "The risk of lymphoma in patients with psoriasis, " Journal of InvestigativeDermatology, vol. 126, no. 10, pp. 2194-2201, 2006.
83. C. G. Mullighan, S. Heatley, S. Lester, M. Rischmueller, T. P. Gordon, and P. G. Bardy, "Fas gene promoter polymorphisms in primary Sjögren's syndrome, " Annals of the Rheumatic Diseases, vol. 63, no. 1, pp. 98-101, 2004.
84. Y. Yoshida, Y. Takahashi, H. Yamashita, T. Kano, H. Kaneko, and A. Mimori, "Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis, " Modern Rheumatology, vol. 24, no. 5, pp. 763-765, 2014.
85. K. Ikeda, T. Nakamura, T. Kinoshita et al., "Methotrexaterelated lymphoproliferative disorder of the stomach in a patient with rheumatoid arthritis: a case of disease regression after methotrexate cessation, " Clinical Journal of Gastroenterology, vol. 9, no. 1, pp. 17-21, 2016.
86. Y. Hoshida, J.-X. Xu, S. Fujita et al., "Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication, " Journal of Rheumatology, vol. 34, no. 2, pp. 322-331, 2007.
87. E. Salloum, D. L. Cooper, G. Howe et al., "Spontaneous regression of lymphoproliferative disorders in patients treated withmethotrexate for rheumatoid arthritis and other rheumatic diseases, " Journal of Clinical Oncology, vol. 14, no. 6, pp. 1943-1949, 1996.
88. C. Salliot and D. van der Heijde, "Long-term safety of methotrexate monotherapy in patientswith rheumatoid arthritis: a systematic literature research, " Annals of the Rheumatic Diseases, vol. 68, no. 7, pp. 1100-1104, 2009.
89. A. Kandiel, A. G. Fraser, B. I. Korelitz, C. Brensinger, and J. D. Lewis, "Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine, " Gut, vol. 54, no. 8, pp. 1121-1125, 2005.
90. T. Bongartz, A. J. Sutton, M. J. Sweeting, I. Buchan, E. L. Matteson, and V. Montori, "Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials, " Journal of the American Medical Association, vol. 295, no. 19, pp. 2275-2285, 2006.
91. S. L. Brown, M. H. Greene, S. K. Gershon, E. T. Edwards, and M. M. Braun, "Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration, " Arthritis and Rheumatism, vol. 46, no. 12, pp. 3151-3158, 2002.
92. D. A. Clark, "Do anti-TNF- drugs increase cancer risk in rheumatoid arthritis patients?" Inflammopharmacology, vol. 21, no. 2, pp. 125-127, 2013.
93. R. Midgard, E. Glattre, M. Grønning, T. Riise, A. Edland, and H. Nyland, "Multiple sclerosis and cancer in Norway a retrospective cohort study, " Acta Neurologica Scandinavica, vol. 93, no. 6, pp. 411-415, 1996.
94. M.-L. Sumelahti, E. Pukkala, and M. Hakama, "Cancer incidence inmultiple sclerosis: a 35-year follow-up, " Neuroepidemiology, vol. 23, no. 5, pp. 224-227, 2004.
95. L. Wideroff, G. Gridley, L. Mellemkjaer et al., "Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark, " Journal of the National Cancer Institute, vol. 89, no. 18, pp. 1360-1365, 1997.
96. K. Zendehdel, O. Nyrén, C.-G. OStenson, H.-O. Adami, A. Ekbom, and W. Ye, "Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden, " Journal of the National Cancer Institute, vol. 95, no. 23, pp. 1797-1800, 2003.
97. J. Askling, J. Grunewald, A. Eklund, G. Hillerdal, andA. Ekbom, "Increased risk for cancer following sarcoidosis, " American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 5, part 1, pp. 1668-1672, 1999.
98. F. K. Rømer, P. Hommelgaard, and G. Schou, "Sarcoidosis and cancer revisited: a long-term follow-up study of 555 Danish sarcoidosis patients, " European Respiratory Journal, vol. 12, no. 4, pp. 906-912, 1998.
99. N. Seersholm, J. Vestbo, and K. Viskum, "Risk of malignant neoplasms in patients with pulmonary sarcoidosis, " Thorax, vol. 52, no. 10, pp. 892-894, 1997.
100. C. S. Hampe, "B cells in autoimmune diseases, " Scientifica, vol. 2012, Article ID215308, 18 pages, 2012.
101. M. Libra, D. Gasparotto, A. Gloghini, P. M. Navolanic, V. De Re, and A. Carbone, "Hepatitis C virus (HCV) infection and lymphoproliferative disorders, " Frontiers in Bioscience, vol. 10, no. 2, pp. 2460-2471, 2005.
102. L. Arcaini, S. Burcheri, A. Rossi et al., "Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT, " Annals of Oncology, vol. 18, no. 2, pp. 346-350, 2007.
103. T. M. Gibson, K. E. Smedby, C. F. Skibola et al., "Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium, " Cancer Causes and Control, vol. 24, no. 1, pp. 125-134, 2013.
104. S. Ekblom-Kullberg, H. Kautiainen, P. Alha, M. Leirisalo-Repo, and H. Julkunen, "Smoking and the risk of systemic lupus erythematosus, " Clinical Rheumatology, vol. 32, no. 8, pp. 1219-1222, 2013.
105. T. N. Sergentanis, P. Kanavidis, T. Michelakos, and E. T. Petridou, "Cigarette smoking and risk of lymphoma in adults: a comprehensive meta-analysis on Hodgkin and non-Hodgkin disease, " European Journal of Cancer Prevention, vol. 22, no. 2, pp. 131-150, 2013.
106. K. Lundberg, C. Bengtsson, N. Kharlamova et al., "Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/ peptide antibody fine specificity profile, " Annals of the Rheumatic Diseases, vol. 72, no. 5, pp. 652-658, 2013.
107. T. R. Mikuls, J. O. Endo, S. E. Puumala et al., "Prospective study of survival outcomes in non-Hodgkin's lymphoma patientswith rheumatoid arthritis, " Journal of Clinical Oncology, vol. 24, no. 10, pp. 1597-1602, 2006.
108. M. Ehrenfeld, M. Abu-Shakra, D. Buskila, and Y. Shoenfeld, "The dual association between lymphoma and autoimmunity, " Blood Cells, Molecules, and Diseases, vol. 27, no. 4, pp. 750-756, 2001.